Head-to-head evidence
Evolocumab vs HRS-1301
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline
Evolocumab · Repatha
Marketed by Amgen
NCT01516879 · Phase 3 · completed
The study randomly assigned 905 participants to quadruple-blinded monthly evolocumab or placebo, with both groups continuing background lipid-lowering therapy. The primary endpoint was met, with a statistically significant difference in LDL-C change at week 52, but LDL-C is a surrogate laboratory endpoint rather than a clinical outcome.
Next expected readout: November 2026 · NCT06496243 (registry estimate)
HRS-1301
Developed by Jiangsu Hengrui Pharmaceuticals and partners
NCT06857253 · Phase 1 · completed
This is a real randomized, blinded, placebo-controlled study, which is a solid design, but its primary measure is adverse-event safety monitoring rather than a cholesterol or cardiovascular outcome, and results have not been posted yet.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Evolocumab's landscape · HRS-1301's landscape